Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMGN NASDAQ:GILD NASDAQ:ILMN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$339.30+0.6%$345.10$267.83▼$391.29$182.10B0.442.82 million shs1.57 million shsGILDGilead Sciences$134.36+3.0%$136.27$104.46▼$157.29$162.02B0.316.24 million shs5.97 million shsILMNIllumina$144.41-0.3%$130.45$78.55▼$155.53$21.91B1.421.71 million shs906,001 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+0.56%+3.98%-1.91%-9.46%+25.05%GILDGilead Sciences+2.96%+3.69%+1.10%-11.25%+24.73%ILMNIllumina-0.29%+1.31%+10.66%+22.72%+81.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$339.30+0.6%$345.10$267.83▼$391.29$182.10B0.442.82 million shs1.57 million shsGILDGilead Sciences$134.36+3.0%$136.27$104.46▼$157.29$162.02B0.316.24 million shs5.97 million shsILMNIllumina$144.41-0.3%$130.45$78.55▼$155.53$21.91B1.421.71 million shs906,001 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+0.56%+3.98%-1.91%-9.46%+25.05%GILDGilead Sciences+2.96%+3.69%+1.10%-11.25%+24.73%ILMNIllumina-0.29%+1.31%+10.66%+22.72%+81.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMGNAmgen 2.48Hold$355.194.68% UpsideGILDGilead Sciences 2.86Moderate Buy$156.9316.80% UpsideILMNIllumina 2.28Hold$137.75-4.61% DownsideCurrent Analyst Ratings BreakdownLatest GILD, ILMN, and AMGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026AMGNAmgen ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$400.00 ➝ $375.005/20/2026GILDGilead Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$165.005/19/2026GILDGilead Sciences Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$161.00 ➝ $150.005/14/2026ILMNIllumina Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$170.005/14/2026AMGNAmgen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$432.00 ➝ $427.005/14/2026ILMNIllumina Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy5/14/2026ILMNIllumina Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$155.005/13/2026AMGNAmgen Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$410.00 ➝ $390.005/11/2026GILDGilead Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/11/2026GILDGilead Sciences Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$170.00 ➝ $167.005/8/2026GILDGilead Sciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$175.00 ➝ $168.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMGNAmgen$36.75B4.98$34.00 per share9.98$17.03 per share19.92GILDGilead Sciences$29.44B5.67$10.78 per share12.46$18.87 per share7.12ILMNIllumina$4.34B5.03$6.69 per share21.57$17.69 per share8.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMGNAmgen$7.71B$14.3723.6114.403.3920.96%137.41%13.28%8/4/2026 (Estimated)GILDGilead Sciences$8.51B$7.3418.3114.03N/A30.99%48.19%18.28%8/6/2026 (Estimated)ILMNIllumina$850M$5.5026.2624.562.4019.42%31.01%12.22%7/30/2026 (Estimated)Latest GILD, ILMN, and AMGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GILDGilead Sciences$1.91$2.03+$0.12$1.61$6.91 billion$6.96 billion4/30/2026Q1 2026AMGNAmgen$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion4/30/2026Q1 2026ILMNIllumina$1.05$1.15+$0.10$0.87$1.07 billion$1.09 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMGNAmgen$10.082.97%+8.27%70.15%14 YearsGILDGilead Sciences$3.282.44%+3.04%44.69%10 YearsILMNIlluminaN/AN/AN/AN/AN/ALatest GILD, ILMN, and AMGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GILDGilead Sciencesquarterly$0.822.45%6/15/20266/15/20266/29/20263/4/2026AMGNAmgenquarterly$2.523.09%5/15/20265/15/20266/5/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMGNAmgen5.651.261.01GILDGilead Sciences0.891.971.77ILMNIllumina0.561.751.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMGNAmgen76.50%GILDGilead Sciences83.67%ILMNIllumina89.42%Insider OwnershipCompanyInsider OwnershipAMGNAmgen0.85%GILDGilead Sciences0.30%ILMNIllumina2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMGNAmgen31,500539.68 million535.10 millionOptionableGILDGilead Sciences17,0001.24 billion1.24 billionOptionableILMNIllumina8,650151.30 million146.91 millionOptionableGILD, ILMN, and AMGN HeadlinesRecent News About These CompaniesDiamond Hill Capital Management Inc. Sells 15,626 Shares of Illumina, Inc. $ILMNMay 22 at 4:40 AM | marketbeat.comDavid P. King elected to Illumina's Board of DirectorsMay 21 at 6:07 PM | finance.yahoo.comDavid P. King elected to Illumina's Board of DirectorsMay 21 at 4:15 PM | prnewswire.comIllumina, Inc. $ILMN is Eagle Health Investments LP's 5th Largest PositionMay 21 at 7:19 AM | marketbeat.comIs This the Right Time to Retain ILMN Stock in Your Portfolio?May 20 at 10:22 AM | finance.yahoo.com3 Reasons to Sell ILMN and 1 Stock to Buy InsteadMay 20 at 10:22 AM | finance.yahoo.comIs This the Right Time to Retain ILMN Stock in Your Portfolio?May 20 at 9:40 AM | zacks.comEarnings Beat, Buyback, China Signals Might Change The Case For Investing In Illumina (ILMN)May 19, 2026 | finance.yahoo.comIllumina Earnings Call Signals Confident Clinical PivotMay 19, 2026 | tipranks.comIllumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impactMay 19, 2026 | finance.yahoo.comIllumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impactMay 19, 2026 | prnewswire.com3 reasons to sell ILMN and 1 stock to buy insteadMay 19, 2026 | msn.com17,065 Shares in Illumina, Inc. $ILMN Purchased by North Dakota State Investment BoardMay 19, 2026 | marketbeat.comCapstone Capital Management Ltd Acquires New Position in Illumina, Inc. $ILMNMay 19, 2026 | marketbeat.comThis Beaten-Down Growth Stock Could Soar 30%, According to Wall StreetMay 18, 2026 | fool.comStephens Investment Management Group LLC Purchases 47,094 Shares of Illumina, Inc. $ILMNMay 17, 2026 | marketbeat.comBank of America Securities Sticks to Its Sell Rating for Illumina (ILMN)May 16, 2026 | theglobeandmail.comThrivent Financial for Lutherans Has $78.79 Million Stock Position in Illumina, Inc. $ILMNMay 16, 2026 | marketbeat.comKeith Meister Sells 104,393 Shares of Illumina (NASDAQ:ILMN) StockMay 16, 2026 | americanbankingnews.comKeith Meister Sells 225,067 Shares of Illumina (NASDAQ:ILMN) StockMay 16, 2026 | americanbankingnews.comIllumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC SaysMay 15, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGILD, ILMN, and AMGN Company DescriptionsAmgen NASDAQ:AMGN$339.30 +1.88 (+0.56%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$340.28 +0.98 (+0.29%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Gilead Sciences NASDAQ:GILD$134.36 +3.86 (+2.96%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$134.17 -0.19 (-0.14%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.Illumina NASDAQ:ILMN$144.41 -0.42 (-0.29%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$144.40 -0.01 (-0.01%) As of 05/22/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
